Machiraju Phani Krishna, Alex Neetu Mariam, Vadamalai Vivek
Department of Internal Medicine, Apollo Hospitals, Chennai, India.
Department of Nephrology, Apollo Hospitals, Chennai, India.
Can J Kidney Health Dis. 2021 Dec 22;8:20543581211067069. doi: 10.1177/20543581211067069. eCollection 2021.
Hyponatremia (serum Na < 135 mmol/L) is the most common electrolyte abnormality detected in clinical practice and an important cause of mortality and morbidity in hospital settings. Hyponatremia in patients with pneumonia is usually mild but is associated with increased risk of intensive care unit (ICU) admission, prolonged hospital stays, and increased mortality rates. The purpose of this study is to understand the impact of varying degrees of hyponatremia and various other inflammatory markers on the severity and outcome of coronavirus disease-19 (COVID-19).
The main objective of this study is to evaluate the prevalence of hyponatremia in COVID-19 patients and to assess the correlation between hyponatremia and severity and outcome of COVID-19. The other objective is to evaluate the correlation between various inflammatory markers and outcome (ICU vs non-ICU admission, discharged vs deceased) in patients with COVID-19 pneumonia.
A total of 113 participants who have been diagnosed with COVID-19 infection by reverse transcriptase-polymerase chain reaction test were included in the study. Epidemiological, demographic, clinical, investigative work-up, and outcome data were extracted from electronic health records using a standard data collection form. Based on serum sodium levels, patients were divided into two groups: normonatremic (serum Na ≥ 135 mEq/L) and hyponatremic (serum Na < 135 mEq/L). Various clinical, laboratory, and outcome parameters were compared between the two groups.
Hyponatremia was present in 50 out of 113 (44%) patients in our study, and it was generally mild. There were more male patients in hyponatremia group ( = .006), and hyponatremic patients were older than normonatremic patients ( = .001). Forty (35%) of the 113 patients were transferred to the ICU, and 17 (15%) needed mechanical ventilation during their hospitalization. Interleukin-6 (IL-6) levels were higher in the hyponatremic group ( = .022). Intensive care unit admissions and oxygen requirement were significantly higher in hyponatremic patients ( = .001 and .016, respectively). Ferritin, lactate dehydrogenase (LDH), IL-6, total leucocyte count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were significantly elevated in those patients requiring ICU admission and those who died due to COVID-19.
Our study revealed that demography, clinical features, radiographic findings, complications like renal insufficiency, and inflammatory markers like IL-6 play a considerable role in hyponatremic COVID-19 patients. Hyponatremia patients required significantly higher rates of ICU admissions and oxygen support. Our results suggest that monitoring inflammatory markers such as ESR, CRP, total white blood cell (WBC) count, ferritin, LDH, and IL-6 may serve as an early warning system for progression to severe COVID-19.
低钠血症(血清钠<135 mmol/L)是临床实践中最常见的电解质异常,也是医院环境中死亡率和发病率的重要原因。肺炎患者的低钠血症通常较轻,但与重症监护病房(ICU)收治风险增加、住院时间延长和死亡率上升有关。本研究的目的是了解不同程度的低钠血症和各种其他炎症标志物对冠状病毒病19(COVID-19)严重程度和预后的影响。
本研究的主要目的是评估COVID-19患者低钠血症的患病率,并评估低钠血症与COVID-19严重程度和预后之间的相关性。另一个目的是评估各种炎症标志物与COVID-19肺炎患者预后(ICU与非ICU收治、出院与死亡)之间的相关性。
本研究共纳入113名经逆转录聚合酶链反应检测确诊为COVID-19感染的参与者。使用标准数据收集表从电子健康记录中提取流行病学、人口统计学、临床、检查结果和预后数据。根据血清钠水平,将患者分为两组:血钠正常(血清钠≥135 mEq/L)和低钠血症(血清钠<135 mEq/L)。比较两组之间的各种临床、实验室和预后参数。
在我们的研究中,113名患者中有50名(44%)存在低钠血症,且通常较轻。低钠血症组男性患者更多(P = 0.006),低钠血症患者比血钠正常患者年龄更大(P = 0.001)。113名患者中有40名(35%)被转入ICU,17名(15%)在住院期间需要机械通气。低钠血症组白细胞介素-6(IL-6)水平更高(P = 0.022)。低钠血症患者的ICU收治率和吸氧需求显著更高(分别为P = 与0.001和0.016)。在需要入住ICU的患者和因COVID-19死亡的患者中,铁蛋白、乳酸脱氢酶(LDH)、IL-6、白细胞总数、红细胞沉降率(ESR)和C反应蛋白(CRP)水平显著升高。
我们的研究表明,人口统计学、临床特征、影像学表现、肾功能不全等并发症以及IL-6等炎症标志物在低钠血症COVID-19患者中起相当大的作用。低钠血症患者的ICU收治率和吸氧支持需求显著更高。我们的结果表明,监测ESR、CRP、白细胞(WBC)总数、铁蛋白、LDH和IL-6等炎症标志物可能作为COVID-19进展为重症的早期预警系统。